Back to List View Graph View

Vascular endothelial growth factor receptor 2 (VEGFR2)

KDR, also known as Kinase Insert Domain-containing Receptor or VEGFR2, is a receptor tyrosine kinase that plays a critical role in vascular development and angiogenesis.

Where the papers sit

19 papers from the last 6 months study Vascular endothelial growth factor receptor 2 (VEGFR2) directly · updated from PubMed 15 Nov 2026

  • VEGFR2 Inhibitor Discovery

    VEGFR2 inhibitor development is moving from sorafenib-inspired scaffolds toward diverse sulfonamide, pyrazole, benzimidazole and quinolinone chemotypes. Computational pharmacophore, QSAR, docking and AI design are repeatedly paired with biochemical or cellular testing. Multi-target activity and antiproliferative effects are common goals, while caspase activation appears as one proposed mechanism. The evidence remains mainly preclinical, leaving potency, selectivity and in vivo efficacy open.

    7 papers · 36.8%

  • Biomarker-Guided Cancer Treatment

    Cancer treatment is moving toward biomarker-defined response prediction using integrated molecular, immune and microbiome data. Machine-learning and network analyses seek signatures linked to progression-free survival, treatment benefit and immune niches across several tumor types. Sorafenib-based therapy shows a biomarker-defined survival signal, while indirect comparisons assess competing antiangiogenic treatments. The recurring question is whether complex signatures can improve patient selection beyond clinical stage and histology.

    5 papers · 26.3%

  • VEGFR-Targeted Combination Therapy

    VEGFR-directed treatment is being combined with cytotoxic agents, pathway inhibitors and additional targets rather than used alone. Fruquintinib with TAS-102 is evaluated in colorectal and gastric cancer, while new compounds pair VEGFR2 inhibition with TGF-βR1 or PDGFR and carbonic anhydrase II blockade. VEGFA/VEGFR2 signaling is also being examined as a predictor of EGFR-TKI outcomes. Antitumor growth and neovascularization remain the main endpoints, with clinical translation still unresolved.

    4 papers · 21.1%

  • Angiogenesis-Targeted Therapy

    Angiogenesis-targeted treatment spans systemic tyrosine-kinase inhibition, HIF-2α blockade and sustained intraocular sorafenib delivery. Renal cancer work emphasizes hypoxia biology and treatment safety, including blood-pressure control during VEGF-pathway therapy. Ocular studies pursue durable suppression of neovascularization while limiting repeated injections and blindness risk. The shared direction is more selective or localized pathway inhibition, but the clinical settings remain distinct.

    3 papers · 15.8%

Papers

The 19 papers from the last 6 months that study Vascular endothelial growth factor receptor 2 (VEGFR2) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

VEGFR2 Inhibitor Discovery (7)
  1. Design, synthesis, and biological evaluation of quinolin-2-one/thiazole hybrids as multi-targeted antiproliferative agents inducing caspase-dependent apoptosis. Scientific reports · 7 Sept 2026 PMID 42706361
  2. In silico and in vitro evaluation of new sulfonamide derivatives as VEGFR-2 inhibitors for cancer therapy. Future medicinal chemistry · 25 Aug 2026 PMID 42639921
  3. Computational identification of potential VEGFR2 inhibitors using integrated pharmacophore modeling, QSAR analysis, molecular docking, dynamics simulation, and virtual screening followed by in vitro bioassays. Journal of computer-aided molecular design · 21 Aug 2026 PMID 42629463
  4. Targeting myoferlin by 6-shogaol inhibition regulates hyperglycemia-induced retinal vascular dysfunction. Phytomedicine : international journal of phytotherapy and phytopharmacology · 18 Jul 2026 PMID 42470951
  5. Starved of oxygen and fueled by macrophages: Path to progression in RCC. Cancer cell · 13 Jul 2026 PMID 42442342
  6. Benzimidazole-Based VEGFR-2 Inhibitors Inspired by Sorafenib: Synthesis, Biological Evaluation, and Mechanistic Insights. Drug development research · 1 Jul 2026 PMID 42381467
  7. Applying artificial intelligence and machine learning framework for de novo design of pyrazole-based VEGFR-2 inhibitors. Journal of molecular graphics & modelling · 28 May 2026 PMID 42208487
Biomarker-Guided Cancer Treatment (5)
  1. Sorafenib/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma. Scientific reports · 2 Sept 2026 PMID 42680778
  2. Integrated Multi-Omics Analysis of Gut Microbiota-Associated Metabolites and Related Host Molecular Signatures in Cervical Squamous Cell Carcinoma. Applied biochemistry and biotechnology · 25 Aug 2026 PMID 42640410
  3. Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma. Journal of comparative effectiveness research · 12 Aug 2026 PMID 42583940
  4. Multi-omics fusion with machine learning enables robust prediction of treatment response in ovarian cancer for precision population health. NPJ digital medicine · 13 Jul 2026 PMID 42443519
  5. Integrated Network Pharmacology and Machine Learning to Reveal the Mechanisms of Schisandrin A Against Triple-Negative Breast Cancer. Journal of cellular and molecular medicine · 1 Jun 2026 PMID 42220063
VEGFR-Targeted Combination Therapy (4)
  1. Combining fruquintinib with TAS-102 as a promising strategy: antitumor activity in preclinical colorectal and gastric cancer xenograft models. BMC cancer · 31 Jul 2026 PMID 42533327
  2. Structure-based design, synthesis, and biological evaluation of benzofuran derivatives as dual TGF-βR1 and VEGFR2 inhibitors for potent antitumor therapy. Bioorganic chemistry · 16 Jul 2026 PMID 42462521
  3. First Discovery of the Dual-Functional Inhibitor Targeting VEGFR/PDGFR/CA II for the Treatment of Neovascular Glaucoma. Journal of medicinal chemistry · 17 Jun 2026 PMID 42308467
  4. Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer. British journal of cancer · 2 Jun 2026 PMID 42231027
Angiogenesis-Targeted Therapy (3)
  1. Intraocular delivery of crystalline sorafenib provides sustained, potent inhibition of wet age-related macular degeneration. Journal of controlled release : official journal of the Controlled Release Society · 18 Jun 2026 PMID 42314988
  2. Discovery of Casdatifan, Part II: A Potent and Orally Bioavailable Inhibitor of Hypoxia Inducible Factor-2α. Journal of medicinal chemistry · 5 Jun 2026 PMID 42246926
  3. Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191. Hypertension (Dallas, Tex. : 1979) · 20 May 2026 PMID 42158981

By study type

Clinical trials (2)
  1. Matching-adjusted indirect comparison of fruquintinib versus ramucirumab in advanced gastric or gastroesophageal junction adenocarcinoma. Journal of comparative effectiveness research · 12 Aug 2026 PMID 42583940
  2. Cluster Randomized Controlled Trial of Intensive Systolic Blood Pressure Control in Patients With Renal Cell or Thyroid Cancer Receiving VEGFR Tyrosine Kinase Inhibitors: ECOG-ACRIN EAQ191. Hypertension (Dallas, Tex. : 1979) · 20 May 2026 PMID 42158981
Observational studies and case reports (1)
  1. Role of VEGFA/VEGFR2 signaling in predicting clinical outcomes of EGFR-TKI treatment in EGFR-mutant non-small cell lung cancer. British journal of cancer · 2 Jun 2026 PMID 42231027
Human data, design not indexed (1)
  1. Applying artificial intelligence and machine learning framework for de novo design of pyrazole-based VEGFR-2 inhibitors. Journal of molecular graphics & modelling · 28 May 2026 PMID 42208487
Preclinical: animal, cell and lab studies (13)
  1. Design, synthesis, and biological evaluation of quinolin-2-one/thiazole hybrids as multi-targeted antiproliferative agents inducing caspase-dependent apoptosis. Scientific reports · 7 Sept 2026 PMID 42706361
  2. Sorafenib/piroxicam therapy with biomarker-defined survival benefit in canine muscle-invasive urothelial carcinoma. Scientific reports · 2 Sept 2026 PMID 42680778
  3. In silico and in vitro evaluation of new sulfonamide derivatives as VEGFR-2 inhibitors for cancer therapy. Future medicinal chemistry · 25 Aug 2026 PMID 42639921
  4. Computational identification of potential VEGFR2 inhibitors using integrated pharmacophore modeling, QSAR analysis, molecular docking, dynamics simulation, and virtual screening followed by in vitro bioassays. Journal of computer-aided molecular design · 21 Aug 2026 PMID 42629463
  5. Combining fruquintinib with TAS-102 as a promising strategy: antitumor activity in preclinical colorectal and gastric cancer xenograft models. BMC cancer · 31 Jul 2026 PMID 42533327
  6. Targeting myoferlin by 6-shogaol inhibition regulates hyperglycemia-induced retinal vascular dysfunction. Phytomedicine : international journal of phytotherapy and phytopharmacology · 18 Jul 2026 PMID 42470951
  7. Structure-based design, synthesis, and biological evaluation of benzofuran derivatives as dual TGF-βR1 and VEGFR2 inhibitors for potent antitumor therapy. Bioorganic chemistry · 16 Jul 2026 PMID 42462521
  8. Starved of oxygen and fueled by macrophages: Path to progression in RCC. Cancer cell · 13 Jul 2026 PMID 42442342
  9. Benzimidazole-Based VEGFR-2 Inhibitors Inspired by Sorafenib: Synthesis, Biological Evaluation, and Mechanistic Insights. Drug development research · 1 Jul 2026 PMID 42381467
  10. Intraocular delivery of crystalline sorafenib provides sustained, potent inhibition of wet age-related macular degeneration. Journal of controlled release : official journal of the Controlled Release Society · 18 Jun 2026 PMID 42314988
  11. First Discovery of the Dual-Functional Inhibitor Targeting VEGFR/PDGFR/CA II for the Treatment of Neovascular Glaucoma. Journal of medicinal chemistry · 17 Jun 2026 PMID 42308467
  12. Discovery of Casdatifan, Part II: A Potent and Orally Bioavailable Inhibitor of Hypoxia Inducible Factor-2α. Journal of medicinal chemistry · 5 Jun 2026 PMID 42246926
  13. Integrated Network Pharmacology and Machine Learning to Reveal the Mechanisms of Schisandrin A Against Triple-Negative Breast Cancer. Journal of cellular and molecular medicine · 1 Jun 2026 PMID 42220063
Unclassified: not yet indexed with MeSH (2)
  1. Integrated Multi-Omics Analysis of Gut Microbiota-Associated Metabolites and Related Host Molecular Signatures in Cervical Squamous Cell Carcinoma. Applied biochemistry and biotechnology · 25 Aug 2026 PMID 42640410
  2. Multi-omics fusion with machine learning enables robust prediction of treatment response in ovarian cancer for precision population health. NPJ digital medicine · 13 Jul 2026 PMID 42443519